Chief, Medical Oncology, Professor of Medicine, University of Kentucky College of Medicine, Markey Cancer Center
Oncology
Dr. Lowell B. Anthony, MD
|
|
Give Review
Dr. Lowell B. Anthony is an expert in the field of Oncology. He researched medicine at Vanderbilt University School of Medicine. He has 3 awards "America's Top Doctors", "America's Top Doctors for Cancer" and "Super Doctor". Lowell Anthony is also published. He has 54 publications published. The lastest publication: "The cost-effectiveness of octreotide acetate in the treatment of carcinoid syndrome and VIPoma.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Appropriateness of Systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.
- A Single Institution's Experience with Surgical CytoreDuction of Stage IV, Well-Differentiated, Small Bowel Neuroendocrine Tumors.
- Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors.
- Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors.
- Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process.
- Deregulation of Wnt/?-catenin signaling through genetic or epigenetic alterations in human neuroendocrine Tumors.
- Practical guide to supportive care of patients with functional neuroendocrine Tumors.
- Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study.
- Neurokinin A levels predict survival in patients with stage IV well differentiated small bowel Neuroendocrine neoplasms.
- Radioguided Exploration Facilitates Surgical CytoreDuction of Neuroendocrine Tumors.
- Evaluating the characteristics and the management of patients with neuroendocrine Tumors receiving octreotide LAR during a 6-year period.
- Safety review: dose optimization of somatostatin Analogs in patients with acromegaly and neuroendocrine tumors.
- Neuroendocrine Tumors: current recommendations for diagnosis and surgical management.
- NANETS treatment guidelines: well-differentiated neuroendocrine Tumors of the stomach and pancreas.
- The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine Tumors (nets): well-differentiated nets of the distal colon and rec...
- Neuroendocrine Tumors: a critical appraisal of management strategies.
- 90Y-edotreotide for metastatic carcinoid refractory to octreotide.
- From somatostatin to octreotide LAR: evolution of a somatostatin Analogue.
- In vitro chemoresistance testing in well-differentiated carcinoid Tumors.
- A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic coloRectal cancer.
- Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine Tumors.
- Irinotecan toxicity.
- Prevention and management of chemotherapy-induced diarrhea in patients with coloRectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Indu...
- A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial.
- New thoughts on the pathobiology of regimen-related mucosal injury.
- Elevation of serum riboflavin carrier protein in hepatoCellular carcinoma.
- Surgical treatment of advanced-stage carcinoid Tumors: lessons learned.
- Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin Analogs.
- New strategies for the prevention and reduction of Cancer treatment-induced diarrhea.
- CytoreDuctive surgery in patients with advanced-stage carcinoid tumors.
- Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.
- High-dose indium 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor.
- In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives.
- Long-acting formulations of somatostatin Analogues.
- Experiences with high dose radiopeptide therapy: the health physics perspective.
- Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in Malignant carcinoid syndrome.
- The cost-effectiveness of octreotide acetate in the treatment of carcinoid syndrome and VIPoma.
- Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease.
- Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid Tumors.
- In situ radiotherapy with 111In-pentetreotide: initial observations and future directions.
- Somatostatin receptor imaging: predictive and prognostic considerations.
- Consensus Statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel.
- Case report: lanreotide in the management of hypercalcemia of malignancy.
- Case report: diabetic ketoacidosis in a patient with glucagonoma.
- Cytochrome P-450IID6 phenotyping in Cancer patients: debrisoquin and dextromethorphan as probes.
- Somatostatin Analogue phase I trials in neuroendocrine neoplasms.
- Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reDuction in 4-hydroxylation.
- Resolution of musculoskeletal symptoms in the carcinoid syndrome after treatment with the somatostatin Analog octreotide.
- The effect of cimetidine on cyclophosphamide metabolism in rabbits.
- A review of ceftriaxone: a long-acting cephalosporin.
- Identification of etoposide glucuronide as a major metabolite of etoposide in the rat and rabbit.
- Antiemetic effect of Oral versus intravenous metoclopramide in patients receiving cisplatin: a randomized, double-blind trial.
- Pneumocystis carinii pneumonia: a complication of Cushing's syndrome.
Schools
Vanderbilt University
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Super Doctor
Education
-
Vanderbilt University -
Vanderbilt University School of Medicine
Hospital
-
University of Kentucky Albert B. Chandler Hospital
Drug Facts
| NPI NUMBER | 1184622250 | |
| NPPES Provider LastName | ANTHONY | |
| NPPES Provider FirstName | LOWELL | |
| NPPES Provider ZIPCode | 405360001 | |
| NPPES Provider State | KY | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 422.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 60.0 | |
| Percent Opioid Claims | 14.22 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1184622250 |
| Last Name Of The Provider | ANTHONY |
| First Name Of The Provider | LOWELL |
| View All |
Similar Doctors
|
|
Dr. John J. Gohmann, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kent E. Taylor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susanne M. Arnold, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hayder Saeed, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arvinda Padmanabhan, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jessica J. Croley, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Aruna Arekapudi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elvis S. Donaldson Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dana A. Johnson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mara D. Chambers, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lee G. Hicks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael E. Horn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suleiman A. Massarweh, MD
This Doctor is OpenDoctor Recommended.
|